Auron Therapeutics

In June 2025, LLS made an equity investment in Auron Therapeutics to "Support Clinical Development of AUTX-703 in Relapsed/Refractory AML and MDS."

Auron Therapeutics is a platform-powered company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease. Auron pioneered its AURIGIN platform, which uses AI and machine learning to compare cell states and identify novel drug targets, optimal development models, and biomarkers to facilitate proper patient selection, ultimately accelerating the development of effective and durable therapies.  

Leveraging its AURIGIN platform, KAT2A/B was identified as a key driver of cell plasticity and disease. AUTX-703 is a first-in-class, oral KAT2A/B degrader and is being evaluated in a Phase 1 dose escalation and dose optimization study in patients with relapsed/refractory AML or MDS (NCT06846606).

For more information about Auron visit aurontx.com.

Recent News

• Coming soon